RLMD Stock Analysis: Relmada Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 473m USD | 12M Return: 197.4% | US75955J4022 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 4.24M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Relmada Therapeutics, Inc. (NASDAQ: RLMD) is a U.S.-based, clinical-stage biotechnology company headquartered in Coral Gables, Florida, and founded in 2004. The company is focused on developing therapies across oncology and central nervous system (CNS) disorders, and is listed on NASDAQ as a Small Cap stock within the Health Care / Pharmaceuticals sub-industry.
The companys lead oncology candidate, NDV-01, is a controlled-release intravesical (directly into the bladder) formulation of two established chemotherapy agents, gemcitabine and docetaxel, currently in Phase 2 clinical trials for aggressive forms of non-muscle invasive bladder cancer (NMIBC). Its second program, Sepranolone, is a neurosteroid epimer of allopregnanolone and is Phase 2b-ready for potential indications including Prader-Willi syndrome, Tourette syndrome, excessive tremor, and other conditions associated with excessive GABAergic activity. Relmada has development agreements in place with Asarina Pharma AB and Trigone to support these programs.
As a clinical-stage biotech, Relmada does not yet have approved or revenue-generating products, and its valuation is largely tied to the progress of its drug pipeline and clinical trial outcomes rather than current sales. Key risks typical for the sector include clinical trial setbacks, regulatory decisions, and future capital-raising needs to fund development.
- NDV-01 Phase 2 bladder cancer data readout in 2025
- Sepranolone Phase 2b enrollment progresses across multiple CNS indications
- Cash burn and capital raises weigh on small-cap valuation
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.21 > 0.02 and ΔFCF/TA 215.4 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.21 > 3% & CFO -46.0m > Net Income -61.9m |
| Net Debt/EBITDA: error (cannot be calculated) |
| Current Ratio: 29.52 > 1.5 & < 3 |
| Outstanding Shares: last quarter (112.4m) vs 12m ago 238.6% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.97 (Total Current Assets 219.0m - Total Current Liabilities 7.42m) / Total Assets 219.1m |
| B: -3.33 (Retained Earnings -730.2m / Total Assets 219.1m) |
| C: -0.54 (EBIT TTM -65.1m / Avg Total Assets 120.1m) |
| D: 16.52 (Book Value of Equity 206.6m / Total Liabilities 12.5m) |
| Altman-Z'' = 9.17 = AAA |
As of September 12, 2026, the stock is trading at USD 4.52 with a total of 2,628,978 shares traded. Over the past week, the price has changed by +3.43%, over one month by +1.12%, over three months by -30.67% and over the past year by +197.37%.
Current recommended Stop Loss: 4.20 (which is 7.1% or 1.3 ATR below the current price).
Relmada Therapeutics has received a consensus analysts rating of 3.00. Therefore, it is recommended to hold RLMD.
- StrongBuy: 0
- Buy: 0
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 12.4 | 174.3% |
P/S = 9001.8951
P/B = 2.3032
Revenue TTM = 0.0 USD
EBIT TTM = -65.1m USD
EBITDA TTM = -65.1m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 254.8m USD (472.5m + (null Debt) - CCE 217.7m)
Interest Coverage Ratio = unknown (Ebit TTM -65.1m / Interest Expense TTM 0.0)
EV/FCF = -5.54x (Enterprise Value 254.8m / FCF TTM -46.0m)
FCF Yield = -18.05% (FCF TTM -46.0m / Enterprise Value 254.8m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 1.16 (Enterprise Value 254.8m / Total Assets 219.1m)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -51.5m (EBIT -65.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 29.52 (Total Current Assets 219.0m / Total Current Liabilities 7.42m)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA -65.1m)
Debt / FCF = unknown (Net Debt none / FCF TTM -46.0m)
Total Stockholder Equity = 130.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -51.57% (Net Income -61.9m / Total Assets 219.1m)
RoE = -47.52% (Net Income TTM -61.9m / Total Stockholder Equity 130.3m)
RoCE = -30.78% (EBIT -65.1m / Capital Employed (Total Assets 219.1m - Current Liab 7.42m))
RoIC = -24.31% (negative operating profit) (NOPAT -51.5m / Invested Capital 211.6m)
WACC = 7.79% (E(472.5m)/V(472.5m) * Re(7.79%) + (debt-free company))
Discount Rate = 7.79% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 81.99 | Cagr: 79.50%
[DCF] Fair Price = unknown (Cash Flow -46.0m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.59 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.14 | Chg30d=+32.24% | Revisions=+25% | Analysts=4
EPS current Year (2026-12-31): EPS=-0.48 | Chg30d=+0.00% | Revisions=-25% | GrowthEPS=+56.4% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-0.56 | Chg30d=-16.67% | Revisions=-25% | GrowthEPS=-16.7% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -17% (up=1, down=2)